1-Pamitoyl-2-Linoleoyl-3-Acetyl-rac-Glycerol May Reduce Incidence of Gemcitabine-Induced Neutropenia: A Pilot Case-Controlled Study

Overview

Journal World J Oncol

Specialty Oncology

Date 2017 Oct 7

PMID 28983339

Citations 1

Authors

Dongwook Oh

Myung-Hwan Kim

Tae Jun Song

Charles J Cho

Kwangwoo Nam

Min Keun Cho

Joo Hyun Chun

Kyoungwon Jung

Kyu-Pyo Kim

Jae Wha Kim

Affiliations

Soon will be listed here.

Abstract

Background: Chemotherapy-induced neutropenia (CIN) may compromise planned chemotherapy, resulting in severe infection, dose reduction or delayed treatment. Orally administered 1-pamitoyl-2-linoleoyl-3-acetyl-rac-glycerol (PLAG) is a synthetic monoacetyldiglyceride, a product found in the antlers of sika deer. The aim of this study was to evaluate the effectiveness of PLAG for the prevention of CIN.

Methods: A total of 48 patients with unresectable pancreatic cancer received gemcitabine-based palliative chemotherapy. Among those patients, 16 patients received PLAG (500 mg) twice daily from the start of chemotherapy to the completion.

Results: The PLAG group showed a significantly lower incidence of neutropenia (absolute neutrophil count < 1,500 cells/mm, grade 2-4), as compared to the control group (37.5% vs. 81.3%, P < 0.05). The absolute neutrophil counts (ANCs) of the PLAG group significantly less decreased from the baseline level compared to those of the control group (P < 0.05) and this significant difference in the reduction percentage of ANCs between the two groups was sustained throughout the courses of chemotherapy. No adverse events related to PLAG were observed.

Conclusions: PLAG was shown to be clinically effective and safe in reducing the incidence of CIN in pancreatic cancer patients receiving gemcitabine-based chemotherapy.

Citing Articles

Mitigating Effect of 1-Palmitoyl-2-Linoleoyl-3-Acetyl-Rac-Glycerol (PLAG) on a Murine Model of 5-Fluorouracil-Induced Hematological Toxicity.

Jeong J, Kim Y, Lee D, Sohn K, Yoon S, Kim J Cancers (Basel). 2019; 11(11).

PMID: 31752148 PMC: 6896120. DOI: 10.3390/cancers11111811.

References

Crawford J, Dale D, Kuderer N, Culakova E, Poniewierski M, Wolff D . Risk and timing of neutropenic events in adult cancer patients receiving chemotherapy: the results of a prospective nationwide study of oncology practice. J Natl Compr Canc Netw. 2008; 6(2):109-18. DOI: 10.6004/jnccn.2008.0012. View

Scott W, Silberstein L, Flatley R, Ardeshna K, Korostoff N, Dawe S . Cutaneous reaction to pegfilgrastim presenting as severe generalized skin eruption. Br J Dermatol. 2009; 161(3):717-9. DOI: 10.1111/j.1365-2133.2009.09371.x. View

Berlin J, Catalano P, Thomas J, Kugler J, Haller D, Benson 3rd A . Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J Clin Oncol. 2002; 20(15):3270-5. DOI: 10.1200/JCO.2002.11.149. View

Smith T, Khatcheressian J, Lyman G, Ozer H, Armitage J, Balducci L . 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol. 2006; 24(19):3187-205. DOI: 10.1200/JCO.2006.06.4451. View

Bennett C, Djulbegovic B, Norris L, Armitage J . Colony-stimulating factors for febrile neutropenia during cancer therapy. N Engl J Med. 2013; 368(12):1131-9. PMC: 3947590. DOI: 10.1056/NEJMct1210890. View

Colucci G, Labianca R, Di Costanzo F, Gebbia V, Carteni G, Massidda B . Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study. J Clin Oncol. 2010; 28(10):1645-51. DOI: 10.1200/JCO.2009.25.4433. View

Yang H, Kim S, Cho S, Kim M, Seo J, Park J . Purification and structural determination of hematopoietic stem cell-stimulating monoacetyldiglycerides from Cervus nippon (deer antler). Chem Pharm Bull (Tokyo). 2004; 52(7):874-8. DOI: 10.1248/cpb.52.874. View

Schwenkglenks M, Pettengell R, Szucs T, Culakova E, Lyman G . Hodgkin lymphoma treatment with ABVD in the US and the EU: neutropenia occurrence and impaired chemotherapy delivery. J Hematol Oncol. 2010; 3:27. PMC: 2933589. DOI: 10.1186/1756-8722-3-27. View

Yang Z, Yuan J, Di M, Zheng D, Chen J, Ding H . Gemcitabine plus erlotinib for advanced pancreatic cancer: a systematic review with meta-analysis. PLoS One. 2013; 8(3):e57528. PMC: 3589410. DOI: 10.1371/journal.pone.0057528. View

10.

Alvarez-Ruiz S, Penas P, Fernandez-Herrera J, Sanchez-Perez J, Fraga J, Garcia-Diez A . Maculopapular eruption with enlarged macrophages in eight patients receiving G-CSF or GM-CSF. J Eur Acad Dermatol Venereol. 2004; 18(3):310-3. DOI: 10.1111/j.1468-3083.2004.00872.x. View

11.

Karlin L, Darmon M, Thiery G, Ciroldi M, de Miranda S, Lefebvre A . Respiratory status deterioration during G-CSF-induced neutropenia recovery. Bone Marrow Transplant. 2005; 36(3):245-50. PMC: 7092208. DOI: 10.1038/sj.bmt.1705037. View

12.

Aapro M, Cameron D, Pettengell R, Bohlius J, Crawford J, Ellis M . EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer. 2006; 42(15):2433-53. DOI: 10.1016/j.ejca.2006.05.002. View

13.

Weycker D, Li X, Edelsberg J, Barron R, Kartashov A, Xu H . Risk and Consequences of Chemotherapy-Induced Febrile Neutropenia in Patients With Metastatic Solid Tumors. J Oncol Pract. 2014; 11(1):47-54. DOI: 10.1200/JOP.2014.001492. View

14.

Veerappan R, Morrison M, Williams S, Variakojis D . Splenic rupture in a patient with plasma cell myeloma following G-CSF/GM-CSF administration for stem cell transplantation and review of the literature. Bone Marrow Transplant. 2007; 40(4):361-4. DOI: 10.1038/sj.bmt.1705736. View

15.

Zamboni W . Pharmacokinetics of pegfilgrastim. Pharmacotherapy. 2003; 23(8 Pt 2):9S-14S. DOI: 10.1592/phco.23.9.9s.32888. View

16.

Yang H, Park J, Cho S, Yoon J, Kim M, Jhon G . Stimulatory effects of monoacetyldiglycerides on hematopoiesis. Biol Pharm Bull. 2004; 27(7):1121-5. DOI: 10.1248/bpb.27.1121. View

17.

Cunningham D, Chau I, Stocken D, Valle J, Smith D, Steward W . Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J Clin Oncol. 2009; 27(33):5513-8. DOI: 10.1200/JCO.2009.24.2446. View

18.

Gresham G, Wells G, Gill S, Cameron C, Jonker D . Chemotherapy regimens for advanced pancreatic cancer: a systematic review and network meta-analysis. BMC Cancer. 2014; 14:471. PMC: 4097092. DOI: 10.1186/1471-2407-14-471. View

19.

Burris H, Belani C, Kaufman P, Gordon A, Schwartzberg L, Paroly W . Pegfilgrastim on the Same Day Versus Next Day of Chemotherapy in Patients With Breast Cancer, Non-Small-Cell Lung Cancer, Ovarian Cancer, and Non-Hodgkin's Lymphoma: Results of Four Multicenter, Double-Blind, Randomized Phase II Studies. J Oncol Pract. 2010; 6(3):133-40. PMC: 2868638. DOI: 10.1200/JOP.091094. View

20.

Siegel R, Ma J, Zou Z, Jemal A . Cancer statistics, 2014. CA Cancer J Clin. 2014; 64(1):9-29. DOI: 10.3322/caac.21208. View